Literature DB >> 31493470

Guide RNA modification as a way to improve CRISPR/Cas9-based genome-editing systems.

Julia Filippova1, Anastasiya Matveeva2, Evgenii Zhuravlev3, Grigory Stepanov4.   

Abstract

Genome-editing technologies, in particular, CRISPR systems, are widely used for targeted regulation of gene expression and obtaining modified human and animal cell lines, plants, fungi, and animals with preassigned features. Despite being well described and easy to perform, the most common methods for construction and delivery of CRISPR/Cas9-containing plasmid systems possess significant disadvantages, mostly associated with effects of the presence of exogenous DNA within the cell. Transfection with active ribonucleoprotein complexes of Cas9 with single-guide RNAs (sgRNAs) represents one of the most promising options because of faster production of sgRNAs, the ability of a researcher to control the amount of sgRNA delivered into the cell, and consequently, fewer off-target mutations. Artificial-RNA synthesis strategies allow for the introduction of various modified components, such as backbone alterations, native structural motifs, and labels for visualization. Modifications of RNA can increase its resistance to hydrolysis, alter the thermodynamic stability of RNA-protein and RNA-DNA complexes, and reduce the immunogenic and cytotoxic effects. This review describes various approaches to improving synthetic guide RNA function through nucleotide modification.
Copyright © 2019 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  CRISPR/Cas9; Genome editing; Guide RNA; RNA modification; Single-guide RNA

Mesh:

Substances:

Year:  2019        PMID: 31493470     DOI: 10.1016/j.biochi.2019.09.003

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  8 in total

Review 1.  Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies.

Authors:  Kelsie L Becklin; Garrett M Draper; Rebecca A Madden; Mitchell G Kluesner; Tomoyuki Koga; Miller Huang; William A Weiss; Logan G Spector; David A Largaespada; Branden S Moriarity; Beau R Webber
Journal:  CRISPR J       Date:  2022-08

2.  A CRISPR/dCas9 toolkit for functional analysis of maize genes.

Authors:  Irene N Gentzel; Chan Ho Park; Maria Bellizzi; Guiqing Xiao; Kiran R Gadhave; Colin Murphree; Qin Yang; Jonathan LaMantia; Margaret G Redinbaugh; Peter Balint-Kurti; Tim L Sit; Guo-Liang Wang
Journal:  Plant Methods       Date:  2020-10-02       Impact factor: 4.993

3.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

4.  5' modifications to CRISPR-Cas9 gRNA can change the dynamics and size of R-loops and inhibit DNA cleavage.

Authors:  Grace Mullally; Kara van Aelst; Mohsin M Naqvi; Fiona M Diffin; Tautvydas Karvelis; Giedrius Gasiunas; Virginijus Siksnys; Mark D Szczelkun
Journal:  Nucleic Acids Res       Date:  2020-07-09       Impact factor: 16.971

Review 5.  Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.

Authors:  Joanna C Dawes; Anthony G Uren
Journal:  Front Immunol       Date:  2021-08-13       Impact factor: 7.561

6.  Gene editing with CRISPR-Cas12a guides possessing ribose-modified pseudoknot handles.

Authors:  Sunit Jana; Leonora Abdullahu; Eman A Ageely; Ramadevi Chilamkurthy; Daniel O'Reilly; Philip J Jensik; Masad J Damha; Keith T Gagnon
Journal:  Nat Commun       Date:  2021-11-15       Impact factor: 14.919

Review 7.  Triazole-Modified Nucleic Acids for the Application in Bioorganic and Medicinal Chemistry.

Authors:  Dagmara Baraniak; Jerzy Boryski
Journal:  Biomedicines       Date:  2021-05-31

Review 8.  Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies.

Authors:  Quynh Nguyen; Kenji Rowel Q Lim; Toshifumi Yokota
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.